VERAXA Biotech 在納斯達克上市，致力於開發癌症療法
VERAXA Biotech Launches on Nasdaq to Develop Cancer Therapies
Updated at: June 11, 2026 at 01:05 PM
2026年6月11日，總部位於蘇黎世的生物製藥公司VERAXA Biotech AG正式達成了一個重要的里程碑，在納斯達克資本市場掛牌上市。
On June 11, 2026, Zurich-based biopharmaceutical company VERAXA Biotech AG officially reached a major milestone by launching on the Nasdaq Capital Market.
進行業務合併，實現了公開上市的地位。
Following this merger, the firm now trades under the ticker symbol 'VRXA.'
此次轉型對生物技術領域而言是一個重要時刻，為該公司提供了7750萬美元的新資金以推動其發展。
VERAXA specializes in developing advanced cancer therapies, specifically utilizing its proprietary BiTAC platform.
VERAXA專門開發先進的癌症療法，特別是利用其專有的BiTAC平台。
This technology aims to create 'AND-gated' treatments that specifically identify and attack cancer cells while leaving healthy tissue unharmed.
這項技術旨在創造「AND邏輯閘」療法，能夠精確識別並攻擊癌細胞，同時確保健康組織不受傷害。
By focusing on bispecific T-cell engagers and antibody-drug conjugates, the company hopes to improve patient safety and treatment efficacy.
VERAXA的研究源自歐洲分子生物學實驗室，如今已做好充分準備，加速其腫瘤學產品管線的臨床試驗。
As Chairman Oliver R.
正如董事長Oliver R.
Baumann noted, this Nasdaq listing is a pivotal step in scaling their innovative technology and bringing next-generation cancer solutions to patients globally.
Baumann所言，此次納斯達克上市是擴大其創新技術規模，並將下一代癌症解決方案帶給全球患者的關鍵一步。
